000170923 001__ 170923
000170923 005__ 20260430151735.0
000170923 0247_ $$2doi$$a10.11613/BM.2026.020701
000170923 0248_ $$2sideral$$a148988
000170923 037__ $$aART-2026-148988
000170923 041__ $$aeng
000170923 100__ $$aMartinez-Marzo, Eva
000170923 245__ $$aUrinary placental growth factor stability as a critical factor in the reliability of preeclampsia diagnosis
000170923 260__ $$c2026
000170923 5060_ $$aAccess copy available to the general public$$fUnrestricted
000170923 5203_ $$aIntroduction: Placental growth factor (PlGF) is a key biomarker for diagnosing and predicting preeclampsia (PE). While serum-based PlGF assays are well established, urine has emerged as a promising non-invasive alternative matrix. However, the absence of urinary PlGF stability data remains a major preanalytical limitation. This study aimed to assess urinary PlGF stability under common preanalytical conditions, including refrigerated storage and a double freeze-thaw cycle.
Materials and methods: A prospective study was conducted using urine samples from ten pregnant women. Each sample was processed under standard laboratory conditions and aliquoted into five tubes. One aliquot was immediately frozen at - 80 °C (T0), three were stored at 2-8 °C for 48, 96, and 168 hours before freezing, and one underwent a double freeze-thaw cycle. Urinary PlGF concentrations were measured using the Elecsys PlGF immunoassay on Roche Cobas e801 analyzer. Percent degradation (PD%) was calculated relative to baseline. A linear regression model was applied to estimate the time to exceed a maximum permissible instability (MPI) of ± 10 %.
Results: Urinary PlGF remained stable at 2-8 °C for up to 48 hours, with a mean PD% of - 6 % (95% confidence interval (CI): - 9.1 to - 2.8). The regression model (PD% = - 0.0834 x Time (h)) estimated the - 10 % threshold at approximately 120 hours. After a double freeze-thaw cycle, the mean PD% was - 1.5 % (95% CI: - 3.4 to 0.4%).
Conclusions: Urinary PlGF shows acceptable stability for up to 48 hours under refrigeration and is stable over two freeze-thaw cycles. These findings provide essential preanalytical data supporting its potential use in clinical and research settings.
000170923 536__ $$9info:eu-repo/grantAgreement/ES/DGA/B46-20R$$9info:eu-repo/grantAgreement/ES/DGA/B46-23R$$9info:eu-repo/grantAgreement/ES/ISCIII-FEDER/CM22-00045$$9nfo:eu-repo/grantAgreement/ES/ISCIII/FI21-00224$$9info:eu-repo/grantAgreement/ES/ISCIII/PI22-143
000170923 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttps://creativecommons.org/licenses/by/4.0/deed.es
000170923 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000170923 700__ $$0(orcid)0000-0001-5459-1254$$aPeran, Maria
000170923 700__ $$aLerma-Irureta, Juan
000170923 700__ $$aMedel-Martinez, Ana
000170923 700__ $$0(orcid)0000-0001-6795-0367$$aPaules, Cristina$$uUniversidad de Zaragoza
000170923 700__ $$0(orcid)0000-0002-8476-9161$$aOros, Daniel$$uUniversidad de Zaragoza
000170923 700__ $$aFabre, Marta$$uUniversidad de Zaragoza
000170923 7102_ $$11013$$2645$$aUniversidad de Zaragoza$$bDpto. Cirugía$$cÁrea Obstetricia y Ginecología
000170923 7102_ $$11011$$2615$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Medic.Prevent.Salud Públ.
000170923 773__ $$g36, 2 (2026), [9 pp.]$$pBiochemia Medica$$tBiochemia medica$$x1330-0962
000170923 8564_ $$s970688$$uhttps://zaguan.unizar.es/record/170923/files/texto_completo.pdf$$yVersión publicada
000170923 8564_ $$s2280407$$uhttps://zaguan.unizar.es/record/170923/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000170923 909CO $$ooai:zaguan.unizar.es:170923$$particulos$$pdriver
000170923 951__ $$a2026-04-30-13:57:10
000170923 980__ $$aARTICLE